Showing results (261-270 of 280) with videos related to

Sort By:
Pageof 28
Oncoimmunology|August 7, 2023
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancerTatiana V Kudling, James H A Clubb, Santeri Pakola, et al.
The New England Journal of Medicine|February 24, 2006
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancerHeikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Petri Bono, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markersTuuli Ranki, Sari Pesonen, Akseli Hemminki, et al.
The Lancet. Oncology|November 13, 2009
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trialHeikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 29, 2010
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSFAnniina Koski, Lotta Kangasniemi, Sophie Escutenaire, et al.
Oncoimmunology|April 10, 2026
<i>Alistipes</i> and <i>Eggerthella</i> shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolismMirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2024
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I TrialSanteri A Pakola, Katriina J Peltola, James H A Clubb, et al.
Cancer Research|May 21, 2010
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patientsVincenzo Cerullo, Sari Pesonen, Iulia Diaconu, et al.
Anticancer Research|March 9, 2012
Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancerPetteri Hervonen, Heikki Joensuu, Timo Joensuu, et al.
Oncoimmunology|July 18, 2022
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regressionTatiana V Kudling, James H A Clubb, Dafne C A Quixabeira, et al.
Pageof 28